drugset / Trial / NCT00071747

Clinical Study Of Schizophrenia in Both Men and Women

NCT00071747

Phase 3 Completed 176 enrolled GlaxoSmithKline
RandomizedParallel-groupDouble-blindTreatment

Summary

The objective of this study is to evaluate the effectiveness of a marketed drug in the treatment of schizophrenia, as an add-on therapy to antipsychotics over a 12-week period. Subjects with schizophrenia who have been maintained on a stable dose of antipsychotics and who fulfill the screening entrance criteria will have an assessment 1-7 days after the first visit to confirm eligibility.

Timeline

Start
2003-08
Primary completion
Completion
2005-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Lamotrigine Small molecule

Indications